3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Lacey Tezino of REACH, Prabhdeep Singh Sekhon of Gold H2, Jill Chapman of Insperity. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a podcast with the new CEO of a gold hydrogen biotech company, the leader of a health tech program, and an HR expert.


Lacey Tezino, program manager at the Gulf Coast Consortium's Research Evaluation and Commercialization Hub

According to program manager Lacey Tezino, REACH received 31 applications over the course of a month last fall. Photo courtesy

A group of seven groundbreaking scientists has been chosen as the first cohort of a top-flight new program for medical innovators.

Last year, the National Institute of Health (NIH) awarded theGulf Coast Consortium with a $4 million grant. Its use? The Research Evaluation and Commercialization Hub, known as REACH. REACH combines the powers of one of the world’s largest inter-institutional cooperatives — including eight Houston-area medical research organizations— to help accelerate fledgling innovations.

According to program manager Lacey Tezino, REACH received 31 applications over the course of a month last fall.

“They were really solid applications. I was just like, ‘Can we take all of them?’” Tezino tells InnovationMap. Continue reading.

Prabhdeep Singh Sekhon, CEO of Gold H2

Prabhdeep Singh Sekhon joins the Houston Innovators Podcast. Photo courtesy of Gold H2

Using microbes to sustainably unlock low-cost hydrogen sounds like the work of science fiction, but one Houston company is doing just that.

Gold H2, a spin-off company from Cemvita, has bioengineered subsurface microbes to use in wells to consume carbon and generate clean hydrogen. The technology was piloted two years ago by Cemvita, and now, as its own company with a new CEO, it's safe to say Gold H2's on its way.

"First of all, that was groundbreaking," Prabhdeep Singh Sekhon, CEO of Gold H2, says of the 2022 pilot in the Permian Basin, "to be able to use bugs to produce hydrogen within a couple of days."

"2024 is supposed to be the year where Gold H2 takes off," Sekhon, who joined the company in April, tells the Houston Innovators Podcast. "It was one of those opportunities that I couldn't turn down. I had been following the company. I thought, 'here is this innovative tech that's on the verge of providing a ground-breaking solution to the energy transition — what better time to join the team.'" Continue reading.

Jill Chapman, director of early talent programs at Insperity

Ultimately, volunteer programs provide a platform for employees to make a positive impact in the community. Photo courtesy of Insperity

Companies of all sizes and stages can implement community-focused initiatives for volunteering, as Jill Chapman of Insperity explains in a guest column.

"Expanding one’s social responsibility doesn’t have to break the bank," she writes. "Smaller companies trying to make an impact should start by establishing initiatives that lay the foundation for a successful volunteer program. To further build out a volunteer program, leaders should look to their employees to define what organizations or causes they are passionate about."

Chapman provides more details on how to introduce volunteering to your workforce. Continue reading.

Each innovator selected was chosen for their commitment to addressing health care challenges and their sheer brilliance in their subjects. Photo via Getty Images

Collaborative life science organization selects 7 innovators for inaugural Houston cohort

chosen ones

A group of seven groundbreaking scientists has been chosen as the first cohort of a top-flight new program for medical innovators.

Last year, the National Institute of Health (NIH) awarded the Gulf Coast Consortium with a $4 million grant. Its use? The Research Evaluation and Commercialization Hub, known as REACH. REACH combines the powers of one of the world’s largest inter-institutional cooperatives — including eight Houston-area medical research organizations— to help accelerate fledgling innovations.

According to program manager Lacey Tezino, REACH received 31 applications over the course of a month last fall.

“They were really solid applications. I was just like, ‘Can we take all of them?’” Tezino tells InnovationMap.

The seven successful applicants were chosen through technology feedback forums led by experts in each field represented. According to Tezino, some of the industry and subject-matter experts went on to become mentors to the members of the first cohort, while others were simply too busy to contribute more of their time.

But the seven teams that were selected can rest assured that they’re in spectacular hands.

“When you are bringing a novel technology to us, I can find someone who is an expert in almost anything that you're doing within health care technology — everyone's at our fingertips. So when it comes to getting advisors, because we're in the Texas Medical Center, the network that we have in the ecosystem is so rich with health care technology, that the support that those who apply for REACH is sort of unmatched,” Tezino says.

Even more impressive, Tezino explains that there are NIH officers waiting to review the projects. For early-stage entrepreneurs, that means that they will be pushed to gain what will likely be their first NIH and SBIR (small business innovation research) grants.

“We get their plan together and then we basically put them on a platter for the NIH,” says Tezino.

Each innovator selected was chosen for their commitment to addressing health care challenges and their sheer brilliance in their subjects, says Tezino. They include:

  • Fernanda Laezza, from the University of Texas Medical Branch, who is seeking to create next-generation pain medications by developing small-molecule drugs.
  • Robert Y. Tsai, from Texas A&M University Institute for Biosciences and Technology, who is testing a medicated, mucoadhesive patch as a non-invasive treatment of oral precancers.
  • Jean X. Jiang and Johanna Webb, from Riverwalk Therapeutics in San Antonio, who are working on new treatments for metastatic cancer and fibrotic retinal diseases.
  • Nadia German, from Texas Tech University, who seeks to treat triple-negative breast cancer and neuropathic pain with novel drugs.
  • Daniel Diaz and his team at Intelligent Proteins in Houston, who are using AI tools to engineer new proteins for use in cancer treatments.
  • From Texas A&M University, Thomas Kent is developing oxidized carbon nanoparticles to treat mitochondrial diseases, including Friedreich’s ataxia.
  • Mario Escobar, from Rice University, who is advancing a novel biologic gene therapy to treat heart failure.

The REACH program lasts nine months, but before the end of that time, the GCC will have recruited and begun working with the next cohort. Interested scientists can apply for the program on a rolling basis at GCCREACH.org. Tezino says that GCC plans to work with three cohorts a year, so there are ample opportunities for qualified candidates.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice, Houston Methodist award $90K for cancer research projects

seed grants

Rice University’s Synthesis X Center, in partnership with the Houston Methodist Neal Cancer Center, announced earlier this month the organizations would award $90,000 in seed grant funding to two projects that could help fight cancer. One would ease the pain of chemotherapy, while the other could change the way the progression of leukemia is tracked.

“We’re excited to be collaborating with the Neal Cancer Center to support collaborative, novel and interdisciplinary proposals to improve cancer care and outcomes,” Han Xiao, Rice professor of chemistry and the director of the SynthX Center, said in a news release. “Together, we can achieve translational excellence.”

The projects

Chemotherapy is one of the most effective cancer treatments, but it can be hard on the body. The human body doesn’t like being injected with radioactive material, especially the skin around the injection point, which can become extremely irritated. For patients in long-term treatment, the skin irritation can be more than just a bother; it can lead to infections that are dangerous to a compromised immune system.

Angel A Marti, a professor of chemistry at Rice University, and Biana Godin, an associate professor of nanoscience at Houston Methodist Research Institute, are experimenting with metal nanoclusters as a way to block radiation at the injection site. The nanocluster could be applied in a cream or a gel on the skin, serving as a type of shield against the harsh radioactive material.

Meanwhile, Yuan Ma, an assistant professor of chemistry at Rice, and Shu-Hsia Chen, a professor of immunology at Houston Methodist Research Institute, are working with m6A. Discovered in the 1970s, m6A is the most prevalent chemical modifier found in mRNA in mammals. It is prevalent in many cancers, including leukemia.

Ma and Chen are working on measuring the amount of m6A in leukemia to see if it can determine the most effective cancer treatments. The team is also experimenting with ways to shut off m6A to see if it makes current leukemia treatments more effective.

Progress from SynthX

SynthX was first launched in April 2024 to turn research from Rice and Houston Methodist into real-world cancer treatments. Within a year, the center had secured $1.5 million in grant money to work on crossing the blood-brain barrier in brain cancer treatments. These latest awards show that SynthX Center continues to bridge the worlds of research and clinical practice.

“This collaboration reflects a shared commitment to team science in cancer research,” Daniela Matei, the director of the Houston Methodist Neal Cancer Center, added in the release. “These are the types of translational and pioneering projects that lead to transformation in patient care.”'

The SynthX Center awarded $90,000 in seed grants to three teams in 2025 and $80,000 to three teams in 2024.

Tesla self-driving mode wasn't to blame in Houston-area crash, report suggests

Tesla news

Federal safety investigators looking into a runaway Tesla that killed a grandmother in her home say the driver had pressed the accelerator to full speed, suggesting the vehicle's self-driving software was not to blame.

The driver had told police that he had the self-driving software turned on, but a report from the National Transportation Safety Board concluded that he had actually overridden that feature when he pushed hard on the pedal. Moments later the Tesla Model 3 raced down a residential street in Katy, Texas, at highway speeds, slammed into a brick home and killed a 76-year-old woman standing in the front room.

The crash last month drew national attention because Tesla CEO Elon Musk is seeking to reassure the public its self-driving feature is safe as he prepares to turn hundreds of thousands of Teslas already on the road into fully automatic vehicles and begin selling two-seated Cybercabs missing steering wheels and pedals.

The crash came two months after officials at a separate federal agency, the National Highway Traffic Safety Administration, announced it was elevating a 2024 investigation of the self-driving feature to new “engineering analysis” level, raising the possibility of a recall of 3.2 million Tesla vehicles.

That NHTSA probe was triggered by crashes where the self-driving feature failed to alert drivers to take control in fog and other poor visibility conditions.

The agency opened an investigation last year into 58 incidents in which Teslas reportedly violated traffic safety laws while using self-driving technology, leading to more than a dozen crashes and fires and nearly two dozen injuries.

Separate from the National Transportation Safety Board, NHTSA is also looking into the Tesla house crash in Texas, one of 46 “special crash” investigations of Tesla's self-driving or driver-assistance technology in the past decade, according to the agency’s records. In more than a dozen of those crashes, at least one person — a driver, passenger or pedestrian — was killed.

Tesla had originally called its driver assistance software Full Self-Driving, or FSD, but auto experts and regulators complained it was misleading because drivers must always keep their eyes on the road and be ready to take over at any time.

The company has since changed the name to Full Self-Driving (Supervised).

Video of the Katy, Texas, accident shows the Tesla traveling at more than 70 mph (112.65 kilometers per hour), jumping a curb then tearing across a lawn before crushing through a brick wall of a home. A woman standing feet away, Martha Avila, was found amid piles of crumbling plaster, split beams and bits of furniture and rushed to a hospital but died.

Sales of Tesla cars still haven't recovered fully from boycotts last year over Musk's political stands, but the stock is rising anyway as he has successfully shifted attention away from the sales figures. He says they matter less now that the company is on the cusp of major technological advances, such as turning Teslas into hands-free vehicles and having its Optimus robots take over for humans for tasks at home and work.

Tesla stock has risen 22% in the past year and is currently trading at 170 times expected annual earnings compared to 20 for the S&P 500.

For its second-quarter financial results, financial analysts surveyed by FactSet expect earnings per share will barely budge — 32 cents versus 33 cents a year earlier — continuing a sixth quarter streak of flat or falling profits.

London AI startup selects Houston for first U.S. office after $20M raise

welcome to houston

London-based AI firm Applied Computing has announced a $20 million Series A round and a new office in Houston.

The new Bayou City office is Applied Computing’s first in the United States and part of its North American expansion. The company is known for its Orbital AI platform, which is tailored for energy operations.

The funding round was led by Houston-based KBR Inc., with participation from San Francisco-based Databricks Ventures. KBR’s investment was first announced in March.

KBR and Applied Computing have also entered into a multi-year agreement to deliver exclusive AI products for the energy sector. KBR already has integrated Orbital into its INSITE 3.0 platform for energy projects, and is also using the product for ammonia production.

Applied Computing’s Orbital platform combines physics-grounded intelligence with models across chemical engineering, time-series forecasting and language, according to the company. The system analyzes sensor readings and can recognize a facility’s equipment constraints and operator activity. The platform can also allow technicians to run simulations of how a change to a facility could affect the rest of its operations.

According to TechCrunch, Applied Computing will use the $20 million to further explore projects and deployments with the energy sector, hire engineering and research positions, and continue to expand internationally, potentially into the Middle East.

The company is also working on deals with a major U.S. stream operator, TechCrunch reports. And Applied Computing shared on LinkedIn that it plans to announce its first partnership with a major European oil company in the coming weeks.

“Yesterday we showed Orbital live in deployments at our demo day at the Energy Institute in London,” Callum Adamson, CEO and co-founder of Applied Computing, posted on LinkedIn on July 16. “Today, we're announcing the capital to scale it globally as well as the launch of our new offices in Houston and Bangalore. In the weeks following, there will be more announcements on our progress, partnerships and deployments.”

The company opened its Bangalore offices in December.

View All Listings